Impairment of Spike-Timing-Dependent Plasticity at Schaffer Collateral-CA1 Synapses in Adult APP/PS1 Mice Depends on Proximity of Aβ Plaques.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Jan 2021
Historique:
received: 28 12 2020
revised: 24 01 2021
accepted: 25 01 2021
entrez: 12 2 2021
pubmed: 13 2 2021
medline: 8 9 2021
Statut: epublish

Résumé

Alzheimer's disease (AD) is a multifaceted neurodegenerative disorder characterized by progressive and irreversible cognitive decline, with no disease-modifying therapy until today. Spike timing-dependent plasticity (STDP) is a Hebbian form of synaptic plasticity, and a strong candidate to underlie learning and memory at the single neuron level. Although several studies reported impaired long-term potentiation (LTP) in the hippocampus in AD mouse models, the impact of amyloid-β (Aβ) pathology on STDP in the hippocampus is not known. Using whole cell patch clamp recordings in CA1 pyramidal neurons of acute transversal hippocampal slices, we investigated timing-dependent (t-) LTP induced by STDP paradigms at Schaffer collateral (SC)-CA1 synapses in slices of 6-month-old adult APP/PS1 AD model mice. Our results show that t-LTP can be induced even in fully developed adult mice with different and even low repeat STDP paradigms. Further, adult APP/PS1 mice displayed intact t-LTP induced by 1 presynaptic EPSP paired with 4 postsynaptic APs (6× 1:4) or 1 presynaptic EPSP paired with 1 postsynaptic AP (100× 1:1) STDP paradigms when the position of Aβ plaques relative to recorded CA1 neurons in the slice were not considered. However, when Aβ plaques were live stained with the fluorescent dye methoxy-X04, we observed that in CA1 neurons with their somata <200 µm away from the border of the nearest Aβ plaque, t-LTP induced by 6× 1:4 stimulation was significantly impaired, while t-LTP was unaltered in CA1 neurons >200 µm away from plaques. Treatment of APP/PS1 mice with the anti-inflammatory drug fingolimod that we previously showed to alleviate synaptic deficits in this AD mouse model did not rescue the impaired t-LTP. Our data reveal that overexpression of APP and PS1 mutations in AD model mice disrupts t-LTP in an Aβ plaque distance-dependent manner, but cannot be improved by fingolimod (FTY720) that has been shown to rescue conventional LTP in CA1 of APP/PS1 mice.

Identifiants

pubmed: 33573114
pii: ijms22031378
doi: 10.3390/ijms22031378
pmc: PMC7866519
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Amyloid beta-Protein Precursor 0
PSEN1 protein, human 0
Presenilin-1 0
Fingolimod Hydrochloride G926EC510T

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : EU Joint Programme - Neurodegenerative Disease Research
ID : Project No. 643417, jointly supported by BMBF and Horizon 2020

Références

Alzheimers Dement. 2020 Jun;16(6):843-852
pubmed: 32323446
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8895-8900
pubmed: 31004062
Science. 2019 Aug 9;365(6453):559-565
pubmed: 31395777
J Physiol. 2008 Dec 15;586(24):5885-900
pubmed: 18936077
Hippocampus. 1991 Apr;1(2):181-92
pubmed: 1669292
Hum Mol Genet. 2015 Sep 1;24(17):4958-70
pubmed: 26063761
J Neurosci. 2003 Oct 1;23(26):8989-9003
pubmed: 14523101
Neuron. 2015 May 20;86(4):1041-1054
pubmed: 25959732
Int J Mol Sci. 2020 Mar 31;21(7):
pubmed: 32244523
Annu Rev Neurosci. 2004;27:279-306
pubmed: 15217334
Front Synaptic Neurosci. 2011 Nov 03;3:6
pubmed: 22065958
Proc Natl Acad Sci U S A. 1988 Jun;85(11):4051-5
pubmed: 3131773
J Physiol. 2010 Nov 15;588(Pt 22):4475-88
pubmed: 20876200
Alzheimers Dement. 2020 Mar 10;:
pubmed: 32157811
Brain. 2020 Apr 1;143(4):1233-1248
pubmed: 32252068
Sci Rep. 2016 Sep 08;6:32422
pubmed: 27604518
Cereb Cortex. 2019 Jul 22;29(8):3266-3281
pubmed: 30169759
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3410-5
pubmed: 16492745
Med J Islam Repub Iran. 2019 Dec 12;33:135
pubmed: 32280641
Neuroscience. 2013 Dec 19;254:152-9
pubmed: 24055684
Nature. 1993 Jan 7;361(6407):31-9
pubmed: 8421494
Psychoneuroendocrinology. 2019 Apr;102:236-247
pubmed: 30594100
Nat Neurosci. 2012 Jan 29;15(3):349-57
pubmed: 22286176
J Pathol. 2011 Jun;224(2):147-52
pubmed: 21557219
Front Pharmacol. 2019 Jul 16;10:778
pubmed: 31379566
J Neurosci. 1998 Dec 15;18(24):10464-72
pubmed: 9852584
J Alzheimers Dis. 2018;64(2):417-435
pubmed: 29914033
J Neurosci Methods. 2020 Jul 15;341:108797
pubmed: 32479974
PLoS One. 2017 Sep 20;12(9):e0185067
pubmed: 28931075
Neural Plast. 2012;2012:319836
pubmed: 22203915
J Neurosci. 2007 Oct 31;27(44):12025-32
pubmed: 17978044
N Engl J Med. 2010 Jan 28;362(4):329-44
pubmed: 20107219
Pharmacol Res. 2018 Apr;130:385-401
pubmed: 29425728
Sci Rep. 2019 Jul 29;9(1):10972
pubmed: 31358793
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
Nat Rev Neurosci. 2008 Jan;9(1):65-75
pubmed: 18094707
J Neurosci Res. 2014 Aug;92(8):975-80
pubmed: 24664800
Neuromolecular Med. 2019 Sep;21(3):227-238
pubmed: 31313064
Behav Brain Res. 2014 Jul 15;268:88-93
pubmed: 24713151
J Neuropathol Exp Neurol. 2002 Sep;61(9):797-805
pubmed: 12230326
PLoS Comput Biol. 2012;8(4):e1002493
pubmed: 22536151
Am J Pathol. 2007 Oct;171(4):1304-11
pubmed: 17717139
J Clin Invest. 2017 Sep 1;127(9):3240-3249
pubmed: 28862638
Brain Res Bull. 2016 Jun;124:95-102
pubmed: 27066884
J Neurosci. 2009 Apr 29;29(17):5587-96
pubmed: 19403825
Proc Natl Acad Sci U S A. 1986 Jul;83(13):4913-7
pubmed: 3088567
Neurobiol Aging. 2012 Feb;33(2):265-76
pubmed: 20359773
J Physiol. 1998 Feb 15;507 ( Pt 1):237-47
pubmed: 9490845
Int J Mol Sci. 2020 Nov 25;21(23):
pubmed: 33255764
Brain Imaging Behav. 2020 Apr 20;:
pubmed: 32314198
Front Neuroanat. 2014 May 27;8:38
pubmed: 24904307
Neuroimage. 2012 Feb 15;59(4):3309-15
pubmed: 22119654
Neuron. 2012 Aug 23;75(4):556-71
pubmed: 22920249
Neurobiol Aging. 2013 Jun;34(6):1632-43
pubmed: 23337342
Ann Neurol. 2004 Jun;55(6):801-14
pubmed: 15174014
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14230-5
pubmed: 22891354
EMBO Mol Med. 2010 Aug;2(8):306-14
pubmed: 20665634
Neurology. 2007 May 8;68(19):1596-602
pubmed: 17485646
PLoS One. 2013 Apr 12;8(4):e61988
pubmed: 23593505
EMBO Rep. 2006 Sep;7(9):940-6
pubmed: 16906128
Neurotoxicology. 2016 Dec;57:75-86
pubmed: 27637609
Rev Neurosci. 2011;22(4):373-402
pubmed: 21732714
Nat Neurosci. 2005 Feb;8(2):187-93
pubmed: 15657596
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5737-5746
pubmed: 30819889

Auteurs

Machhindra Garad (M)

Institute of Physiology, Medical Faculty, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.

Elke Edelmann (E)

Institute of Physiology, Medical Faculty, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
Center for Behavioral Brain Sciences (CBBS), 39120 Magdeburg, Germany.

Volkmar Leßmann (V)

Institute of Physiology, Medical Faculty, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
Center for Behavioral Brain Sciences (CBBS), 39120 Magdeburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH